Literature DB >> 6746815

Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine.

C H Kleinbloesem, J Van Harten, P Van Brummelen, D D Breimer.   

Abstract

A high-performance liquid chromatographic method was developed for the assay of nifedipine in plasma and its main metabolite (M-I) in urine. After liquid-liquid extraction nifedipine was chromatographed in a reversed-phase system with ultraviolet detection at 238 nm. The method was sensitive to 2 ng nifedipine per ml plasma and the standard curve was linear to at least 400 ng/ml. Standard deviations did not exceed 8.5%. There was no interference with photodecomposition products or metabolites. M-I was determined in urine after liquid-liquid extraction by ion-pair chromatography with ultraviolet detection at 290 nm. The method was sensitive to 0.02 micrograms M-I per ml urine and the standard curve was linear to at least 5 micrograms/ml. Standard deviations did not exceed 5.0%. The methods were used to study nifedipine disposition in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6746815     DOI: 10.1016/s0021-9673(01)87547-6

Source DB:  PubMed          Journal:  J Chromatogr


  14 in total

1.  Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function.

Authors:  W Kirch; A Nokhodian; A Halabi; G Weidinger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

2.  Ethnic differences in the pharmacokinetics of oral nifedipine.

Authors:  C H Ahsan; A G Renwick; B Macklin; V F Challenor; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

4.  Factors affecting the pharmacokinetics of nifedipine.

Authors:  A G Renwick; J Le Vie; V F Challenor; D G Waller; B Gruchy; C F George
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Food and nifedipine pharmacokinetics.

Authors:  V F Challenor; D G Waller; B S Gruchy; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

6.  Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man.

Authors:  J H Schellens; P A Soons; J H van der Wart; J W Hoevers; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 7.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

8.  The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine.

Authors:  A Khan; S J Langley; F G Mullins; J S Dixon; S Toon
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

Review 9.  Nifedipine. Relationship between pharmacokinetics and pharmacodynamics.

Authors:  C H Kleinbloesem; P van Brummelen; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.